Catecholamines have been shown to activate hypothalamic corticotropin-releasing factor-41 (CRF) synthesis and release. In order to study the mechanisms involved, fetal hypothalamic cells were cultured and CRF release was measured by radioimmunoassay. Norepinephrine (NE) induced CRF release in a dose-dependent manner. Further studies were performed with a protein kinase C inhibitor, H-7(l-(5-isoquinolinesulfonyl)-2-methylpiperazine) and a protein kinase A inhibitor, IP-20. NE-stimulated CRF release was reduced by H-7 (5 and 50 µM) in a dose-dependent fashion, while 5 µM IP-20 resulted in a small but significant inhibition. Pretreatment of the cells for 15 h with 20 and 200 nM 12-O-tetradecanoylphorbol-13-acetate, which down-regulates protein kinase C activity, blocked the release of CRF in response to NE (1 µM), further supporting protein kinase C as a mediator for NE-activated CRF release. Pretreatment with 50 and 500 ng/ml pertussis toxin (15 h) resulted in a dose-dependent inhibition of NE-activated CRF release. Both dexamethasone and aldosterone at the concentrations of 1 µM reduced NE-induced CRF release. These results sugget that CRF can be released from hypothalamic neurons in response to NE through both protein kinase C- and protein kinase A-dependent mechanisms, and that pertussis toxin-sensitive G-proteins are also involved in this response. Furthermore, glucocorticoids and mineralocorticoids can reduce NE-acivated CRF release from cultured hypothalamic cells.

Dexamethasone and aldosterone inhibit hypothalamic corticotropin releasing factor-41 (CRF) release. The possible receptors through which these adrenal steroids affect CRF release were studied using rat fetal hypothalamic cell cultures. Neither the antimineralocorticoid RU 28318 nor the antiglucocorticoid RU 38486 alone had any effect on forskolin-stimulated CRF release. RU 38486 and RU 28318 however suppressed dexamethasone (1 µM)- and aldosterone (1 µM)-induced inhibition of forskolin (20 µM)-stimulated CRF release, respectively, suggesting that dexamethasone and aldosterone reduce CRF release through type II and type I corticosteroid receptors, respectively. RU 38486 had no effect on aldosterone-induced inhibition of forskolin-stimulated CRF release, nor did RU 28318 have any effect on dexamethasone-induced inhibition of forskolin-stimulated CRF release, indicating specificity of the binding of aldosterone with type I receptors, and dexamethasone with type II receptors in the hypothalamic cell cultures.